Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches. METHODS: We randomly assigned 1623 patients to lenalidomide and dexamethasone in 28-day cycles until disease progression (535 patients), to the same combination for 72 weeks (18 cycles; 541 patients), or to MPT for 72 weeks (547 patients). The primary end point was progression-free survival with continuous lenalidomide-dexamethasone versus MPT. RESULTS: The median progression-free survival was 25.5 months with continuous lenalidomide-dexamethasone, 20.7 months with 18 cycles of lenalidomide-dexamethasone, and 21.2 months with MPT (hazard ratio for the risk of progression or death, 0.72 for continuous lenalidomide-dexamethasone vs. MPT and 0.70 for continuous lenalidomide-dexamethasone vs. 18 cycles of lenalidomide-dexamethasone; P<0.001 for both comparisons). Continuous lenalidomide-dexamethasone was superior to MPT for all secondary efficacy end points, including overall survival (at the interim analysis). Overall survival at 4 years was 59% with continuous lenalidomide-dexamethasone, 56% with 18 cycles of lenalidomide-dexamethasone, and 51% with MPT. Grade 3 or 4 adverse events were somewhat less frequent with continuous lenalidomide-dexamethasone than with MPT (70% vs. 78%). As compared with MPT, continuous lenalidomide-dexamethasone was associated with fewer hematologic and neurologic toxic events, a moderate increase in infections, and fewer second primary hematologic cancers. CONCLUSIONS: As compared with MPT, continuous lenalidomide-dexamethasone given until disease progression was associated with a significant improvement in progression-free survival, with an overall survival benefit at the interim analysis, among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation. (Funded by Intergroupe, Francophone du Myélome and Celgene; FIRST ClinicalTrials.gov number, NCT00689936; European Union Drug Regulating Authorities Clinical Trials number, 2007-004823-39.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation.”
From Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma (2019) · cites this paper as [5]
In the citing paper
“However, the incidence of grade 3 or 4 infections was 29% with lenalidomide and dexamethasone in the primary analysis of the FIRST trial,5 which was consistent with the incidence in our trial (32.1% in the daratumumab group and 23.3% in the control group).”
From Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma (2019) · cites this paper as [5]
In the citing paper
“In this subset of patients, maintenance therapy with proteasome inhibitors alone or in combination with lenalidomide seems to be more effective than single-agent lenalidomide34,35.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [34]
In the citing paper
“Patients with high-risk cytogenetic features might be the only exception, although they do derive a progression-free survival (PFS) benefit34,35.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [34]
In the citing paper
“The most worrisome adverse effect observed in studies of lenalidomide maintenance therapy is an up to six-fold increase in the risk of second primary malignancies, in particular, MDS and acute myeloid leukaemia (AML): 5.3% versus 0.8% with placebo or observation34.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [34]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationPalumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Self-citationRaje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
Self-citationBortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Self-citationGroup sequential methods in the design and analysis of clinical trials
POCOCK, S. J. (1977) · Biometrika · doi:10.1093/biomet/64.2.191 · Cited by 1,831
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citation
Cited by
Items 701–793 of 793
Les hémopathies malignes du sujet âgé
Poisson, J., & Chaoui, D. (2015) · Soins Gérontologie · doi:10.1016/j.sger.2015.01.004
Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma
Cejalvo, M. J., & de la Rubia, J. (2015) · Future Oncology · doi:10.2217/fon.15.51
Postępy w diagnostyce i leczeniu chorych na szpiczaka plazmocytowego
Jamroziak, K. (2015) · Hematologia · doi:10.5603/hem.2015.0011 · Cited by 1
Patienten profitieren von Dauertherapie mit Lenalidomid/Dexamethason
Schalhorn, B. (2014) · Info Onkologie · doi:10.1007/s15004-014-1018-4
Which Myeloma Therapy for Transplant-Ineligible Patients?
Williams, M. E. (2014) · Journal watch · doi:10.1056/nejm-jw.na35968
Praktische Empfehlungen zu Diagnostik und Therapie
Schmidmaier, R., & Straka, C. (2014) · Info Onkologie · doi:10.1007/s15004-014-0796-z
“Eine Dauertherapie mit Lenalidomid und Dexamethason (Rd) stellt ebenso ein hoche ektives Regime dar [11], das aber in Europa noch nicht zugelassen ist.”
BackgroundHow Should We Treat Elderly Newly Diagnosed Multiple Myeloma Patients?
Mateos, M. (2015) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2015.11.01.43
“In the most remarkable recent study involving 1,623 patients not eligible for transplantation (IFM07-01, MM020) the combination of Len/dex administered until disease progression or intolerance was compared with MPT administered for 72 weeks or Len/dex administered for the same fixed period of time.(19) The trial showe…”
BackgroundTavernier, E., Cornillon, J., Molucon-Chabrot, C., Cahn, J.-Y. Y., Tinquaut, F., Bourmaud, A., Guyotat, D., & Thomas, X. (2016) · Hematology · doi:10.1080/10245332.2016.1255372
“methasone for the treatment of multiple myeloma [6,7] and in combination with rituximab for the treatment of mantle-cell lymphoma [8].”
BackgroundOgiya, D., Shibayama, H., Nakatani, E., Ando, K., Suzuki, K., Kuroda, Y., Uchida, T., Maruyama, D., Matsumoto, M., Matsue, K., et al. (2016) · PubMed · doi:10.11406/rinketsu.57.2311
Stammzelltransplantation auch bei älteren Patienten?
Schreder, M., Strifler, S., & Knop, S. T. (2017) · Info Onkologie · doi:10.1007/s15004-017-5571-5
Study design for vulnerable older adults with multiple myeloma
Nathwani, N., & Wildes, T. M. (2017) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2017.02.007
Targeted therapy and maintenance in myeloma
Mateos, M., & González‐Calle, V. (2017) · British Medical Bulletin · doi:10.1093/bmb/ldx013
Goldschmidt, H., & Weisel, K. C. (2016) · Der Nephrologe · doi:10.1007/s11560-015-0031-4
Self-citationUpdated analysis of CALGB (Alliance) 100104
Boccadoro, M. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30148-5
Strategie optymalizacji terapii lenalidomidem u chorych na szpiczaka plazmocytowego
Szymczyk, A., & Hus, I. (2017) · Acta Haematologica Polonica · doi:10.1016/j.achaem.2017.10.002
Multiples Myelom beim alten und geriatrischen Patienten
Kahl, C. (2018) · Springer eBooks · doi:10.1007/978-3-662-48727-3_20
“Die FIRSTStudie verglich Lenalidomid und Dexamethason bis zur Krankheitsprogression mit 18-monatigen Gabe von Lenalidomid, Dexamethason und MPT (Benboubker et al. 2014).”
BackgroundInfluentialNursing support during treatment of multiple myeloma with proteasome inhibitors
Aerts, E., Szabó, Z. R., & Hellberg-Naegele, M. (2018) · Cancer Nursing Practice · doi:10.7748/cnp.2018.e1488
Justiz-Vaillant, A. A. (2018) · International biological and biomedical journal · Cited by 1
Therapie des multiplen Myeloms bei älteren Patienten
Weyermann, C., Thorspecken, S., & Straka, C. (2018) · Info Onkologie · doi:10.1007/s15004-018-5941-7
van der Poel (2018) · Research Publications (Maastricht University) · doi:10.26481/dis.20180525mp
Miguel, J. F. S., & Bladé, J. (2015) · Wiley eBooks · doi:10.1002/9781118853771.ch29
Multiple Myeloma in Older Adults
Rosko, A. E., Bhatt, G., Lichtman, E. I., & Tuchman, S. A. (2019) · Springer eBooks · doi:10.1007/978-3-319-44870-1_44-1 · Cited by 1
Lenalidomide 使用中の多発性骨髄腫患者における acetylsalicylic acid の使用状況
大輔, 菊., 拓, 小., 良祐, 三., 庄太, 高., 正太, 柏., 浩司, 岡., & 善照, 渡. (2019) · doi:10.11256/jjdi.21.79
Hanamoto, H., Fujii, A., Fujita, M., Fujimoto, K., Fujiwara, R., & Tsubaki, K. (2019) · Internal Medicine - Open Journal · doi:10.17140/imoj-3-109
Plasma cell myeloma and related monoclonal gammopathies
Rajkumar, S. V., & Kyle, R. A. (2020) · doi:10.1093/med/9780198746690.003.0527
Haemopoietic diseases: leukaemias and myelomas
Mina, R., Larocca, A., & Palumbo, A. P. (2017) · doi:10.1093/med/9780198701590.003.0094
Zhang, H., Deng, Q., Li, J. Y., Zhao, M., & Li, Y. M. (2018) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2018.10.016
“[3] Benboubker L, Dimopoulos MA, Dispenzieri A, et al.”
BackgroundJung, N., Mayet, W.-J., Mertens, P. R., (federführend), J. M., Müller, O., Pfeifer, R., Schellinger, P. D., Weiss, N., & Wendtner, C. ‐. (2020) · Elsevier eBooks · doi:10.1016/b978-3-437-06282-7.50009-7
Erstlinientherapie von Patienten mit multiplem Myelom
Renner, C., & Samaras, P. (2020) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-020-8150-0
Onishi, Y., Yokoyama, H., Katsuoka, Y., Ito, T., Kimura, T., Yamamoto, J., Nakajima, S., Sasaki, O., Ara, T., Minauchi, K., et al. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04240-x
Raje, N. S., & Yee, A. J. (2015) · The Hematologist · doi:10.1182/hem.v12.2.3679
Multiples Myelom und andere plasmazelluläre Erkrankungen
Goldschmidt, H., & Weisel, K. C. (2020) · Springer eBooks · doi:10.1007/978-3-662-59911-2_7
Self-citationZhang, P.-F., Zhang, M., Wu, Q., & Li, Q. (2020) · Leukemia Research · doi:10.1016/j.leukres.2020.106444
RetractedAdvances in the management of multiple myeloma
Berenson, J. R., Spektor, T. M., & Wang, J. (2016) · The Journal of Community and Supportive Oncology · doi:10.12788/jcso.0270 · Cited by 1
Maintenance Strategies for Myeloma: Is Bigger Always Better?
Nooka, A. K., & Joseph, N. S. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000524
The Role of Targeted Therapy in Multiple Myeloma
Kwok, A. C. Y., & Ling, S. (2021) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-030-73440-4_1
Bone remodeling: analysis, discussion, and perspectives
Kahla, R. B., & Barkaoui, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-88467-9.00007-2
Recent therapeutic approaches in myeloma
Ntanasis‐Stathopoulos, I., & Terpos, E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821666-8.00060-8
Purdy, G. M. (2021) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-nc8r-s166 · Cited by 1
Multiple Myeloma in Older Adults
Rosko, A. E., Bhatt, G., Lichtman, E. I., & Tuchman, S. A. (2020) · Springer eBooks · doi:10.1007/978-3-319-57415-8_44
Bianchi, G., & Anderson, K. C. (2018) · Wiley eBooks · doi:10.1002/9781118592168.ch33
Self-citationNassar, S., Kaufman, G. P., Taher, A., Madewell, J. E., & Mujtaba, B. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-69538-1.00029-x
Belantamab mafodotin for relapsed or refractory multiple myeloma
Gil‐Sierra, M. D., & Briceño-Casado, M. D. P. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221086265
The clinical value of circulating cell free DNA in multiple myelomaPreprint
Yang, T., Chen, W., Wang, Z., Wei, T., Shang, J., & Lin, Y. H. (2022) · Research Square · doi:10.21203/rs.3.rs-1604204/v1
Schulz, C. (2020) · Elsevier eBooks · doi:10.1016/b978-3-437-21215-4.00014-7
Delforge, M. (2018) · HemaSphere · doi:10.1097/hs9.0000000000000109
Self-citationTantravahi, S. K., & Kovacsovics, T. J. (2015) · Springer eBooks · doi:10.1007/978-1-4614-5662-9_9
Hanna, K. S. (2017) · The American Pharmacists Association eBooks · doi:10.21019/pharmacotherapyfirst.mult-myeloma_overview
Multiples Myelom beim alten und geriatrischen Patienten
Kahl, C. (2017) · Springer eBooks · doi:10.1007/978-3-662-49083-9_20-1
Schulz, C. (2017) · Elsevier eBooks · doi:10.1016/b978-3-437-21214-7.00014-6
Yeung, A. J.-T., & Ling, S. (2021) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-030-73440-4_2
Atanazio, M. J. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2022.tde-15062022-092534
Campbell, R. B., Tran, C., Park, E., & Flores, P. L. R. (2022) · Current Drug Therapy · doi:10.2174/1574885517666220426092902 · Cited by 1
Evaluación de estrategias inmunes para el control del mieloma múltiple a largo plazo
Valls, J. D. (2022) · Gredos (University of Salamanca) · doi:10.14201/gredos.150753
Yee, A. J., Hideshima, T., Raje, N. S., & Anderson, K. C. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm122.pub2
Self-citationBitonti, R., Demma, F., Rea, M., & Furneri, G. (2022) · AboutOpen · doi:10.33393/ao.2022.2447
The Pivotal Role of Proteasome Inhibition in Myeloma Treatment
Cahill, M. (2017) · EMJ Hematology · doi:10.33590/emjhematol/10314234
Oral Therapies for Multiple Myeloma
Singhal, S., & Kumar, S. K. (2022) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2022.18.2.139
“Although it produces a similar or higher rate of cytopenias than thalidomide, the risk of neuropathy is much lower.(44,46,57,60) The safety profile of lenalidomide has been summarized in Table 3.”
BackgroundMultiple myeloma management: What comes after lenalidomide-based therapy?
Louzada, M. (2022) · Canadian Hematology Today · doi:10.58931/cht.2022.1213
Acute Hypoxic Respiratory Failure Due To Lenalidomide-Induced Interstitial PneumonitisPreprint
O’Meara, K., Fansiwala, K. M., Kathuria‐Prakash, N., El‐Masry, M., & Oh, S. (2023) · Research Square · doi:10.21203/rs.3.rs-2917563/v1
Locher, C., Laporte, S., Derambure, P., Chassany, O., Girault, C., Avakiantz, A., Bahans, C., Deplanque, D., Fustier, P., Germe, A.-F., et al. (2023) · Therapies · doi:10.1016/j.therap.2023.10.013
Data Monitoring Committees and clinical trials: From scientific justification to organisation
Locher, C., Laporte, S., Derambure, P., Chassany, O., Girault, C., Avakiantz, A., Bahans, C., Deplanque, D., Fustier, P., Germe, A.-F., et al. (2023) · Therapies · doi:10.1016/j.therap.2023.12.002 · Cited by 1
Toxicity profile of chemotherapy regimens for multiple myeloma patients using CTCAE Criteria
Antony, V., Antony, A., Kurian, H., Jiju, J. A., Thomas, T., Sunny, J. S., & Abraham, S. (2023) · Journal of Innovations in Applied Pharmaceutical Science (JIAPS) · doi:10.37022/jiaps.v8i3-s.506
Thalidomide Analogue Drug Eruption Along the Lines of Blaschko
Jafari, A. J. (2023) · Cutis · doi:10.12788/cutis.0921
Considerations for the treatment of frail multiple myeloma patients
Mohty, M., & Rajkumar, S. V. (2024) · Clinical Hematology International · doi:10.46989/001c.92586 · Cited by 1
Büyükşimşek, M., Tohumcuoğlu, M., Sedef, A. M., Bahçeci, A., Nayır, E., Yılmaz, M., Temi, Y. B., Beşen, A. A., Diker, Ö., Şimşek, M., et al. (2022) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.1538
Introduction to Multiple Myeloma and Multiple Myeloma Bone Disease
Esteghamat, N., & Abedi, M. (2024) · Springer eBooks · doi:10.1007/978-3-031-52001-3_10
Rosenberg, T., Möller, S., Abildgaard, N., Nørgaard, J. N., Lysén, A., Tsykonova, G., Joao, C. M., Vangsted, A. J., Schjesvold, F. H., & Nielsen, L. K. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14358
Mikala, G., Ceglédi, A., & Szemlaky, Z. (2024) · Hematológia–Transzfuziológia · doi:10.1556/2068.2024.00194
Mohyuddin, G. R., Almasri, J., Goodman, A. M., Haslam, A., & Prasad, V. K. (2024) · The Oncologist · doi:10.1093/oncolo/oyae332
“…the doublet of lenalidomide/dexamethasone showed a progression-free survival and overall survival advantage compared with melphalan/prednisone/thalido-mide, 25 likely influencing the decision to keep lenalidomide/ dexamethasone backbone regimens listed on these guidelines while removing others.”
Costello, C. L., & Fonseca, R. (2022) · doi:10.1182/ashsap8.chapter25
Mel, S. D., Tso, A. C. Y., Soekojo, C. Y., Ooi, M. G. M., Lim, C. C., Teo, C., Chen, Y. X., Tan, M. S. Y., Manjeri, A., Lee, Z. Y., et al. (2025) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.202532 · Cited by 1
Seki, J. T., Atenafu, E. G., Bhella, S., Chen, C. I., Trudel, S., Yang, C., Reece, D. E., Rodriguez, J. G. P., Vohra, H. S., Kushwaha, R., et al. (2025) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1155/jcpt/6275323
“In one large clinical trial, the incidence rates of Grade 3/4 rash were twice as high in LEN/POM-containing regimens compared to those without [8].”
Self-citationDrašković, D., Marjanović, G., Vučić, M., & Ćojbašić, I. (2025) · AFMN Biomedicine · doi:10.5937/afmnai41-60811
What Is the Cost Impact of Second Opinions in Oncology? A Retrospective Review
Roman, B. R., Lipitz‐Snyderman, A., Chimonas, S. C., Raftery, B., Manship, C., Mahajan, A., Saltz, L. B., Mitchell, A. P., Miller, D. G., Sihag, S., et al. (2025) · JCO Oncology Practice · doi:10.1200/op-25-00586
Pettas, E., WOO, S., Margalit, D. N., Tishler, R. B., Haddad, R. I., Hanna, G. J., & Treister, N. S. (2026) · Practical Radiation Oncology · doi:10.1016/j.prro.2026.02.005
Iriuchishima, H., Saito, A., Mihara, M., Kanaya, S., Yoshizawa, R., Isoda, A., & Matsumoto, M. (2026) · Cancers · doi:10.3390/cancers18071048
Parcours de soins des patients atteints d'hémopathies malignes en Poitou-Charentes
Puyade, M. (2017) · theses.fr (ABES) · doi:10.70675/a92a89a7z5a27z4a59za2e7z161e1e08e0b4
Lau, G., Chandra, M. B., Fero, H., & Alabbas, F. (2026) · International Journal of Hematology · doi:10.1007/s12185-026-04195-1 · Cited by 1
“For years, continuous treatment with lenalidomide and dexamethasone (Rd) was the standard of care for TIE patients, until being superseded by bortezomib, lenalidomide, and dexamethasone (VRd) in the SWOG S0777 trial [15–17].”
Nückel, H., Behlendorf, T., Schulz, H., Schulze, M. B., Schardt, C., Medinger, T., Koenigsmann, M., Dechow, T. N., Indorf, M., Bürkle, D., et al. (2026) · Cancer Medicine · doi:10.1002/cam4.71758
Développement et évaluation d'anticorps bispécifiques dans le traitement du Myélome multiple
Fayon, M. (2019) · theses.fr (ABES) · doi:10.70675/f357d44fz13a7z4f3bza50cz18ea6c378e17
Exploration des récepteurs à dépendance dans les hémopathies malignes
Fahed, D. (2020) · theses.fr (ABES) · doi:10.70675/621dee0ez6dd8z4539z81a4z388f4a3296af
Tagami, N., Shirai, H., & Hanamura, I. (2026) · Cancer Medicine · doi:10.1002/cam4.71928
Jung, S., Kim, D., Lee, J. H., Choi, D., Lee, W. S., Jung, J., Eom, H., Do, Y. R., Yuh, Y. J., Kim, H. S., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70663
Self-citationMartino, E. A., Vigna, E., Bruzzese, A., Amodio, N., Caserta, S., Lucia, E., D'Arrigo, G., Olivito, V., Labanca, C., Mendicino, F., et al. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70263
2026 Myeloma Treatment Guidelines of the Turkish Myeloma Study Group
Beksaç, M., Mastanzade, M. G., Değirmenci, B. B., Oluk, B., Sağlam, B., Özlük, D. Ö., Cengiz, E., Alhan, F. N., Dikici, H. Z., Uygun, K. Y., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.08.008 · Cited by 3
Kato, Y., Suzuki, T., Kondo, A., Matsunaga, N., Kikuchi, T., Kanamori, T., Yoshida, T., Kayukawa, S., Asao, Y., Yano, H., et al. (2026) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2026.103096
IFM 2026 Recommendations for First-line Treatment of Newly Diagnosed Multiple Myeloma
Perrot, A., Manier, S., Hulin, C., Demarquette, H., Bobin, A., Frenzel, L., Karlin, L., Decaux, O., Mohty, M., Arnulf, B., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.09.002
Self-citationImmunomodulatory Drugs and Cereblon E3 Ligase Modulators in Multiple Myeloma: 30 Years in the Making
Bazarbachi, A. H., Lentzsch, S., Facon, T. T. F., Harousseau, J., & Mohty, M. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-00545
Self-citationGreil, C., Jung, J., Felthaus, J., Wider, D., Engelhardt, M. M., & Wäsch, R. (2026) · Cancers · doi:10.3390/cancers18193093
“…the introduction of targeted immunotherapies, including monoclonal antibodies, antibody–drug conjugates, bispecific antibodies, and chimeric antigen receptor (CAR) T cells, MM is still associated with a substantial burden of morbidity and mortality [1–4], requiring novel therapeutic approaches.”
Dholaria, B., Medvedova, E., Ravi, G., Dhakal, B., Callander, N. S., Godby, K. N., Bal, S., Schmidt, T. M., Silbermann, R. W., & Costa, L. J. (2026) · Leukemia · doi:10.1038/s41375-026-03162-3
Metadata
- Authors
- Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., Banos, A., Tiab, M., Delforge, M., Cavenagh, J., Geraldes, C., Lee, J.-J., Chen, C., Oriol, A., de la Rubia, J., Qiu, L., White, D. J., Binder, D., Anderson, K., Fermand, J.-P., Moreau, P., Attal, M., Knight, R., Chen, G., Van Oostendorp, J., Jacques, C., Ervin-Haynes, A., Avet-Loiseau, H., Hulin, C., & Facon, T.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Mayo Clinic (US)
- Frankston Hospital (AU)
- University of Alberta (CA)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- University of Tübingen (DE)
- Wilhelminen Hospital (AT)
- University of Calgary (CA)
- Centre Hospitalier de la Côte Basque (FR)
- Universitair Ziekenhuis Leuven (BE)
- St Bartholomew's Hospital (GB)
- Unidade Local de Saúde de Coimbra (PT)
- Chonnam National University Hwasun Hospital (KR)
- Princess Margaret Cancer Centre (CA)
- Josep Carreras Leukaemia Research Institute (ES)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Dalhousie University (CA)
- Kantonsspital Winterthur (CH)
- Dana-Farber Cancer Institute (US)
- Hôpital Saint-Louis (FR)
- Hôpital Purpan (FR)
- Celgene (United States) (US)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- ORCID
- Benboubker, Lotfi
- Dimopoulos, Meletios A.
- Dispenzieri, Angela
- Belch, Andrew R.
- Weisel, Katja
- Ludwig, Heinz
- Bahlis, Nizar
- Banos, Anne
- Geraldes, Catarina
- Lee, Je-Jung
- Chen, Christine
- Oriol, Albert
- Qiu, Lugui
- White, Darrell J.
- Anderson, Kenneth
- Fermand, Jean-Paul
- Moreau, Philippe
- Attal, Michel
- Knight, Robert
- Chen, Guang
- Jacques, Christian
- Hulin, Cyrille
- Facon, Thierry
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-09-04
- Volume
- 371
- Issue
- 10
- Pages
- 906-917
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141105112
- Cited by
- 793
- References
- 38
- Citations by year
- 2026: 18 · 2025: 41 · 2024: 39 · 2023: 37 · 2022: 54 · 2021: 74 · 2020: 89 · 2019: 75 · 2018: 80 · 2017: 92 · 2016: 102 · 2015: 76 · 2014: 15
- FWCI
- 67.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- lenalidomide, dexamethasone, multiple myeloma, transplant-ineligible patients, progression-free survival, overall survival, treatment duration, adverse events, second primary malignancy, infection, neurotoxicity, hematologic toxicity, newly diagnosed multiple myeloma
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Melphalan, Middle Aged, Multiple Myeloma, Prednisone, Thalidomide, Disease-Free Survival, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.